A Phase 1, Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Study of FPA008 in Healthy Volunteers and Subjects With Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
Price : $35 *
At a glance
- Drugs Cabiralizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Five Prime Therapeutics
- 13 Sep 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2016.
- 13 Sep 2016 Status changed from recruiting to discontinued.
- 11 Nov 2015 Preliminary efficacy data (n=6) presented at the 79th American College of Rheumatology and the 50th Annual Meeting of the Association of Rheumatology and Health Professionals.